BioAtla Analyst Ratings
BioAtla Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/25/2023 | 682.12% | JP Morgan | $17 → $14 | Maintains | Overweight |
| 08/02/2023 | 849.72% | JP Morgan | $19 → $17 | Maintains | Overweight |
| 08/02/2023 | 570.39% | JMP Securities | → $12 | Reiterates | Market Outperform → Market Outperform |
| 08/02/2023 | 1296.65% | EF Hutton | → $25 | Reiterates | Buy → Buy |
| 08/02/2023 | 849.72% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 05/15/2023 | 570.39% | JMP Securities | $12 → $12 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 849.72% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 05/12/2023 | 1296.65% | EF Hutton | → $25 | Reiterates | Buy → Buy |
| 04/17/2023 | 1296.65% | EF Hutton | → $25 | Maintains | Buy |
| 04/03/2023 | 961.45% | JP Morgan | $23 → $19 | Maintains | Overweight |
| 03/28/2023 | 626.26% | BTIG | $68 → $13 | Maintains | Buy |
| 03/27/2023 | 570.39% | JMP Securities | $17 → $12 | Maintains | Outperform |
| 03/24/2023 | 346.93% | Credit Suisse | → $8 | Reiterates | → Neutral |
| 03/24/2023 | 1296.65% | EF Hutton | → $25 | Reiterates | → Buy |
| 03/24/2023 | 849.72% | HC Wainwright & Co. | $20 → $17 | Maintains | Buy |
| 01/05/2023 | 1296.65% | EF Hutton | → $25 | Initiates Coverage On | → Buy |
| 11/04/2022 | 346.93% | Credit Suisse | $4 → $8 | Maintains | Neutral |
| 09/15/2022 | 849.72% | JMP Securities | → $17 | Initiates Coverage On | → Market Outperform |
| 08/10/2022 | 123.46% | Credit Suisse | $5 → $4 | Maintains | Neutral |
| 08/10/2022 | 1017.32% | HC Wainwright & Co. | $25 → $20 | Maintains | Buy |
| 05/05/2022 | 179.33% | Credit Suisse | $35 → $5 | Downgrades | Outperform → Neutral |
| 03/21/2022 | 1296.65% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 06/28/2021 | 4089.94% | Roth Capital | → $75 | Initiates Coverage On | → Buy |
| 03/26/2021 | 4760.34% | BTIG | $47 → $87 | Maintains | Buy |
| 01/11/2021 | 2637.43% | Credit Suisse | → $49 | Initiates Coverage On | → Outperform |
| 01/11/2021 | 2749.16% | Jefferies | → $51 | Initiates Coverage On | → Buy |
| 01/11/2021 | 2413.97% | JP Morgan | → $45 | Initiates Coverage On | → Overweight |
| 01/11/2021 | 2525.7% | BTIG | → $47 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/25/2023 | 682.12% | 摩根大通 | $17→$14 | 维护 | 超重 |
| 08/02/2023 | 849.72% | 摩根大通 | $19→$17 | 维护 | 超重 |
| 08/02/2023 | 570.39% | JMP证券 | →$12 | 重申 | 市场表现优于→市场表现 |
| 08/02/2023 | 1296.65% | EF Hutton | →$25 | 重申 | 购买→购买 |
| 08/02/2023 | 849.72% | HC Wainwright公司 | →$17 | 重申 | 购买→购买 |
| 2023年05月15日 | 570.39% | JMP证券 | $12→$12 | 重申 | 跑赢→跑赢大盘 |
| 2023年05月15日 | 849.72% | HC Wainwright公司 | →$17 | 重申 | 购买→购买 |
| 2023年05月12日 | 1296.65% | EF Hutton | →$25 | 重申 | 购买→购买 |
| 04/17/2023 | 1296.65% | EF Hutton | →$25 | 维护 | 买 |
| 04/03/2023 | 961.45% | 摩根大通 | $23→$19 | 维护 | 超重 |
| 03/28/2023 | 626.26% | BTIG | $68→$13 | 维护 | 买 |
| 03/27/2023 | 570.39% | JMP证券 | $17→$12 | 维护 | 跑赢大盘 |
| 03/24/2023 | 346.93% | 瑞士信贷 | →$8 | 重申 | →中性 |
| 03/24/2023 | 1296.65% | EF Hutton | →$25 | 重申 | →购买 |
| 03/24/2023 | 849.72% | HC Wainwright公司 | $20→$17 | 维护 | 买 |
| 01/05/2023 | 1296.65% | EF Hutton | →$25 | 开始承保 | →购买 |
| 11/04/2022 | 346.93% | 瑞士信贷 | $4→$8 | 维护 | 中性 |
| 09/15/2022 | 849.72% | JMP证券 | →$17 | 开始承保 | →市场跑赢大盘 |
| 2022年08月10日 | 123.46% | 瑞士信贷 | $5→$4 | 维护 | 中性 |
| 2022年08月10日 | 1017.32% | HC Wainwright公司 | $25→$20 | 维护 | 买 |
| 05/05/2022 | 179.33% | 瑞士信贷 | $35→$5 | 评级下调 | 跑赢→中性 |
| 03/21/2022 | 1296.65% | HC Wainwright公司 | →$25 | 开始承保 | →购买 |
| 2021/06/28 | 4089.94% | 罗斯资本 | →$75 | 开始承保 | →购买 |
| 03/26/2021 | 4760.34% | BTIG | $47→$87 | 维护 | 买 |
| 2021/11/01 | 2637.43% | 瑞士信贷 | →$49 | 开始承保 | →跑赢大盘 |
| 2021/11/01 | 2749.16% | 杰富瑞 | →$51 | 开始承保 | →购买 |
| 2021/11/01 | 2413.97% | 摩根大通 | →$45 | 开始承保 | →超重 |
| 2021/11/01 | 2525.7% | BTIG | →$47 | 开始承保 | →购买 |
What is the target price for BioAtla (BCAB)?
BioAtla(BCAB)的目标价格是多少？
The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on September 25, 2023. The analyst firm set a price target for $14.00 expecting BCAB to rise to within 12 months (a possible 682.12% upside). 17 analyst firms have reported ratings in the last year.
摩根大通于2023年9月25日报道了BioAtla(纳斯达克代码：BCAB)的最新目标价。这家分析公司将目标价定为14美元，预计支行将在12个月内上涨至12个月内(可能上涨682.12)。过去一年，17家分析公司公布了评级。
What is the most recent analyst rating for BioAtla (BCAB)?
BioAtla(BCAB)的最新分析师评级是多少？
The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.
对BioAtla(纳斯达克代码：BCAB)的最新分析师评级由摩根大通提供，BioAtla维持其增持评级。
When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?
BioAtla(BCAB)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与BioAtla的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。BioAtla的上一次评级是在2023年9月25日提交的，所以你应该预计下一次评级将在2024年9月25日左右提供。
Is the Analyst Rating BioAtla (BCAB) correct?
分析师对BioAtla的评级正确吗？
While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $17.00 to $14.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的BioAtla(BCAB)评级维持不变，目标价在17.00美元至14.00美元之间。BioAtla目前的交易价格为1.79美元，超出了分析师的预测范围。